FibroGen seeks to identify and develop innovative drugs with the greatest promise of becoming first-in-class medicines for the treatment of chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis, and pancreatic cancer. The Company’s product candidates leverage the body’s natural pathways allowing investigation of their potential across multiple diseases. FibroGen’s most advanced therapeutic, roxadustat, is an oral small molecule inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase, the enzyme that regulates HIF activity and is being developed for treatment of anemia associated with CKD.
Foresite Capital recently invested in a Fibrogen public secondary offering after following the company for several years. We believe the mechanism behind Fibrogen’s lead drug roxadustat represents a significant technological advance in treating anemia associated CKD. To address the expanding CKD patient population, Fibrogen has partnered with Astellas and AstraZeneca, two large pharmaceutical companies with global commercial sales forces. We believe these key partnerships enable the company to maximize the full CKD anemia commercial opportunity. Fibrogen has also prosecuted roxadustat clinical development in China, and plans to commercialize in this key emerging market by leveraging the global footprint established by their strategic partners.